Novartis replaces top scientists at Avexis unit over drug data manipulation


Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement.

The Kaspars are brothers. Brian Kaspar was a founder and key executive at Avexis and made more.

This article is no longer available in our repository.

There could be multiple reasons for this.